StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO - Free Report) in a report published on Monday morning. The firm issued a strong-buy rating on the medical research company's stock.
Global Cord Blood Stock Performance
CO stock remained flat at $1.15 during midday trading on Monday. The company has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.19. The stock has a market cap of $139.78 million, a P/E ratio of 1.80 and a beta of 0.16. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50.
Global Cord Blood Company Profile
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Stories
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
